These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 13991706)

  • 1. Enzyme-alterable alkylating agents. IV. Treatment of cancer in children with repetitive massive doses of S-46, protecting the extremity marrow by tourniquets.
    SCHILLING A
    Cancer; 1963 Jun; 16():727-36. PubMed ID: 13991706
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective use of a new alkylating agent in children with protection by tourniquets of marrow in the extremities.
    SELIGMAN AM
    Sinai Hosp J (Balt); 1961; 10():91-4. PubMed ID: 13910424
    [No Abstract]   [Full Text] [Related]  

  • 3. THE DURATION OF THE MYELOTOXIC EFFECTS OF CIRCULATING ALKYLATING AGENTS.
    ULFOHN A; KRAMER SP; DORFMAN H; WITTEN B; WILLIAMSON C; SASS S; MILLER JI; SELIGMAN AM
    Cancer Res; 1964 Oct; 24():1659-65. PubMed ID: 14234010
    [No Abstract]   [Full Text] [Related]  

  • 4. RESULTS OF REGIONAL CHEMOTHERAPY OF NEOPLASMS OF THE UPPER BODY BY TEMPORARY MID-TORSO VASCULAR OCCLUSION.
    CLAPP P; TAYAO MS; MILLER DG; LAWRENCE W
    Cancer; 1964 Aug; 17():1012-25. PubMed ID: 14202589
    [No Abstract]   [Full Text] [Related]  

  • 5. Massive nitrogen mustard therapy in Hodgkin's disease with protection of bone marrow by tourniquets.
    CONRAD ME; CROSBY WH
    Blood; 1960 Aug; 16():1089-103. PubMed ID: 13811574
    [No Abstract]   [Full Text] [Related]  

  • 6. Effective use of a new alkylating agent in doses lethal to bone marrow with protection by tourniquets of marrow in the extremis.
    GOODMAN LE; SCHILLING A; KRAMER SP; ULFOHN A; MILLER S; KRAVITZ S; GABY SD; BAKAL D; WITTEN B; SELIGMAN AM
    Surg Forum; 1961; 12():130-2. PubMed ID: 13900321
    [No Abstract]   [Full Text] [Related]  

  • 7. REDUCTION OF THE TOXICITY OF "RADIOMIMETIC" ALKYLATING AGENTS IN RATS BY THIOL PRE-TREATMENT. IV. PROTECTION AGAINST BONE MARROW DAMAGE.
    CONNORS TA; DOUBLE JA; ELSON LA; JENEY A
    Biochem Pharmacol; 1965 Apr; 14():569-77. PubMed ID: 14330623
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of extremity tourniquets in administering nitrogen and chlorimine mustards.
    SNYDER W; GOLDEN RL; MILLER DG; DIAMOND HD
    Cancer Chemother Rep; 1962 Oct; 23():25-9. PubMed ID: 13993169
    [No Abstract]   [Full Text] [Related]  

  • 9. [REGIONAL CHEMOTHERAPY OF MALIGNANT TUMORS. II. TREATMENT WITH MASSIVE DOSES OF NITROGEN MUSTARD WITH TEMPORARY COMPRESSION OF THE ABDOMINAL AORTA AND ITS COLLATERAL ARTERIES].
    OETTGEN HF; CLIFFORD P; BEECHER JL; GILLMORE JH
    Klin Wochenschr; 1964 Mar; 42():218-24. PubMed ID: 14169591
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzyme alterable alkylating agents. X. Experimental study of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy.
    Ulfohn A; Kramer SP; Calle S; Sass S; Williamson CE; Witten B; Seligman AM
    J Surg Res; 1968 Aug; 8(8):345-59. PubMed ID: 5667860
    [No Abstract]   [Full Text] [Related]  

  • 11. Enzyme-alterable alkylating agents. IX. The enzymatic transformation of some nitrogen mustards in the presence of carbon dioxide: implications in respiration.
    Williamson CE; Kirby JG; Miller JI; Sass S; Kramer SP; Seligman AM; Witten B
    Cancer Res; 1966 Feb; 26(2):323-30. PubMed ID: 5903181
    [No Abstract]   [Full Text] [Related]  

  • 12. [THE INFLUENCE ON CARBOHYDRATE METABOLISM OF TUMORS OF CHOMOTHERAPEUTIC DRUGS].
    KROEGER H
    Z Naturwiss Med Grundlagenforsch; 1963 Apr; 1():126-42. PubMed ID: 14159165
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of inoperable cancer of the lung, bladder and liver by means of intra-arterial administration of alkylating agents and application of remote control vessel tourniquet; a preliminary report.
    Jozef Z; Tadeusz J
    Pol Med Sci Hist Bull; 1966 Oct; 9(4):178-80 passim. PubMed ID: 5920141
    [No Abstract]   [Full Text] [Related]  

  • 14. STUDIES OF THE MODE OF ACTION OF TUMOUR-GROWTH-INHIBITING ALKYLATING AGENTS. IV. IN-VITRO REACTIONS OF 2-CHLOROETHYLARYLAMINES.
    ROBERTS JJ; WARWICK GP
    Biochem Pharmacol; 1963 Dec; 12():1315-9. PubMed ID: 14096418
    [No Abstract]   [Full Text] [Related]  

  • 15. EXPERIMENTAL CHEMOTHERAPY STUDIES. IV. THE PROTECTIVE ACTION OF MERCAPTOALKYLAMINES AGAINST ALKYLATING AGENTS.
    RUTMAN RJ; LEWIS FS; PRICE CC
    Cancer Res; 1964 May; 24():626-33. PubMed ID: 14188465
    [No Abstract]   [Full Text] [Related]  

  • 16. [NITROGEN MUSTARDS AS ALKYLATING AGENTS].
    MANACORDA G; POMINI A
    Minerva Farm; 1964; 13():89-94. PubMed ID: 14268580
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparative investigation of the chemotherapeutic action of N-oxide-mustard gas and other alkylating compounds in rat tumors].
    DANNEBERG P; DRUCKREY H; KAISER K; LO HW; MECKE R; NIEPER HA; SCHMAHL D
    Arzneimittelforschung; 1956 Sep; 6(9):539-50. PubMed ID: 13373668
    [No Abstract]   [Full Text] [Related]  

  • 18. Nitrogen-mustard therapy combined with autologous marrow infusion.
    CLIFFORD P; CLIFT RA; DUFF JK
    Lancet; 1961 Apr; 1(7179):687-90. PubMed ID: 13694099
    [No Abstract]   [Full Text] [Related]  

  • 19. EFFECT OF HEPARIN-BOUND ALKYLATING AGENTS AND ENZYME INHIBITORS ON NEOPLASTIC GROWTH.
    CSABA G; KOROESI J; HORVATH C; MOLD K; ACS T
    Neoplasma; 1964; 11():137-44. PubMed ID: 14160693
    [No Abstract]   [Full Text] [Related]  

  • 20. Disseminated abdominal melanoma treated by massive dosage of nitrogen mustard and autogenous bone-marrow replacement.
    JONES KO; REEVE TS; PIPER DW; CUMBERLAND VH
    Med J Aust; 1960 Jul; 47(2)():61-3. PubMed ID: 14407740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.